EXPEREO
10.4.2024 15:01:30 CEST | Business Wire | Press release
Expereo, the world leading global intelligent internet company that connects people, places and things anywhere today announces the appointment of Ben Elms as Chief Executive Officer and Irwin Fouwels as Executive Chairman, effective May 1st, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410648166/en/
Ben Elms (Photo: Business Wire)
This strategic move is part of Expereo's commitment to driving sustained growth and building on its legacy of innovation and global customer success. With their combined experience in the telecommunications and technology sectors, Elms and Fouwels bring a wealth of expertise and leadership to their new roles within the business.
As CEO, Ben Elms will be responsible for driving the company's strategic vision, enhancing operational efficiency, and fostering innovation to meet the evolving needs of Expereo's global customer base. He brings over 25 years of relevant experience having held key executive roles at prominent firms and prior to joining Expereo as the CEO of Vodafone Global Enterprise Business, serving its multinational customers around the world.
Since joining in 2022 as Chief Revenue Officer, Elms has successfully led transformative initiatives such as expereoOne Expereo’s digital customer experience platform and driven its direct enterprise go-to-market strategy. This has positioned Expereo as a recognized global leader in delivering unique transformative customer value through its global enterprise network and cloud access solutions. In the first quarter of this year, Expereo launched its Enhanced Internet proposition, optimizing global cloud application performance through a proprietary AI-driven routing optimization platform. Leveraging Elms’ strong background in IoT and mobility, Expereo also added enterprise grade Fixed Wireless Access and Low Orbit Satellite solutions to its wide array of managed global connectivity solutions.
Elms commented; "I am honoured to lead Expereo during this exciting next phase of growth and innovation. Expereo has established itself as a global leader in internet-based connectivity solutions, and I look forward to working closely with the talented team to drive further success and deliver unparalleled value to our direct enterprise and wholesale customers. We have a strong foundation and a reputation for excellence in the industry. I am thrilled to lead the company with Irwin’s support as Executive Chairman. With the entire team we will capitalize on new opportunities, further expand our market presence, and drive continued innovation including driven by increased adoption of AI and the opportunities that creates for Expereo – “faster to the future”."
Fouwels, assuming the role of Executive Chairman brings a strategic mindset and a passion for innovation which has contributed to Expereo’s success. As Expereo CEO over the last decade, he has transformed and scaled Expereo to the world leading global intelligent internet company delivering unparalleled internet performance, led the company through multiple investor rounds and a series of acquisitions whilst delivering strong financial performance and investor returns.
Fouwels commented; “It is a privilege working with the global Expereo team and its investment partners over the last decade delivering unique value to our customers in a dynamic technology and telecoms market. We have been pivotal in transforming the way global enterprises architect global connectivity and application performance, leveraging the agility of the internet, whilst making it enterprise grade in terms of performance and security. And this anywhere on the globe, through any access technology.
Over the last two years Ben as CRO has been invaluable in accelerating our growth path, strengthening our go to market in direct enterprise whilst ensuring scalability throughout the organization, driving further automation, transformation and building global recognition of the Expereo brand and notably transforming expereoOne to a unique digital customer experience and platform. expereoOne turns the fragmented global internet landscape into a unique one-touch customer experience and has grown significantly with the addition of a large number of globally recognised large multinational enterprise customers. Ben has also brought in exceptional talent, strengthening the team as a foundation for further growth and solid financial performance. I am very much looking forward to working alongside Ben providing strategic guidance and supporting Expereo's leadership team”.
With Elms’ and Fouwels’ combined leadership, industry knowledge and track record of success they are confident in accelerating Expereo’s growth trajectory, and in delivering exceptional value to their customers and partners.
About Expereo
Expereo is the world leading intelligent internet company that connects people, places, and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to any location worldwide, working with over 2,300 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility, and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners which acquired a majority shareholding from Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410648166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom